The Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Opinion
Video

An expert on the treatment of multiple myeloma discusses the role of CAR T-cell therapy in relapsed/refractory disease.

Recent Videos
4 KOLs are featured in this series.
4 KOLs are featured in this series.
A panel of 5 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Adding bortezomib to Isa-Rd triplet therapy enhanced MRD-negative responses in patients with transplant-ineligible multiple myeloma.
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Related Content
Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.

Novel BCL-2 Inhibitor Combo Shows Enduring Responses in R/R Myeloma Subtype

Ryan Scott
October 5th 2024
Article

Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.

Isatuximab Combo Yields MRD-Negative Responses in Transplant-Eligible NDMM

Jordyn Sava
October 4th 2024
Article

Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Multiple myeloma

HDP-101 Demonstrates Preliminary Efficacy in R/R Multiple Myeloma

Russ Conroy
October 2nd 2024
Article

Investigators anticipate launching the dose-expansion portion of the phase 1 HDP-101-01 trial in 2025.

A nurse practitioner discussed how her role plays a vital part in patient care for those undergoing talquetamab treatment for multiple myeloma.

Assessing NP Roles in Talquetamab Treatment for Multiple Myeloma

Roman Fabbricatore
October 1st 2024
Article

A nurse practitioner discussed how her role plays a vital part in patient care for those undergoing talquetamab treatment for multiple myeloma.